A Head-to-Head Comparison of Two Antibodies for HER2 Pretargeted PET Imaging via Bioorthogonal Click Chemistry
Open Access
- 13 August 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (8) , 1276
Abstract
Background/Objectives: Antibody selection is critical for advancing pretargeted PET imaging toward clinical translation. This study directly compared two clinically approved anti-HER2 antibodies—trastuzumab and pertuzumab—within an identical pretargeting system, utilizing the specific chemical ligation between tetrazine and trans-cyclooctene (TCO) via the inverse electron-demand Diels–Alder (IEDDA) cycloaddition. Methods: In HER2-positive SKOV3 tumor-bearing mice, TCO-conjugated antibodies were administered 1–13 days prior to injection of a fluorine-18-labeled tetrazine probe ([18F]PEG12-Tz). Results: Both strategies enabled high-contrast imaging, overcoming the kinetic mismatch between slow-clearing antibodies and the short-lived 18F isotope. Distinct profiles were observed: pertuzumab-TCO yielded higher tumor uptake and a broader imaging window (3–13 days), whereas trastuzumab-TCO resulted in lower uptake and a narrower window (1–5 days). These differences are not affinity-driven, as both conjugates showed similar Kd values (~11–14 nM). Instead, pertuzumab-TCO’s superiority stems from a dual mechanism: (1) slower cellular internalization (65.1% vs. 94.0% at 60 min) preserves surface TCO for click reaction; and (2) markedly slower blood clearance (t1/2β = 285.9 h vs. 106.0 h) ensures sustained bioavailability and tumor extravasation. Conclusions: This head-to-head evaluation demonstrates that epitope-dictated internalization and clearance are decisive parameters for antibody selection, providing a mechanism-based framework for optimizing pretargeted imaging.Keywords
Funding Information
- National Natural Science Foundation of China (82102115)
- National Natural Science Foundation of China (82373212)
- Shenzhen High-level Hospital Construction Fund, the Shenzhen Science and Technology Program of China (JCYJ20220818101804009)
- Shenzhen Clinical Research Center for Cancer ((2021) 287)
This publication has 36 references indexed in Scilit:
- Bioorthogonal Diels–Alder Click Chemistry-Based Pretargeted PET Imaging Strategy for Monitoring Programmed Death-Ligand 1 ExpressionACS Omega, 2024
- Antibody Pretargeting Based on Bioorthogonal Click Chemistry for Cancer Imaging and Targeted Radionuclide TherapyBioconjugate Chemistry, 2019
- Radioactive Transition Metals for Imaging and TherapyChemical Reviews, 2018
- Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast CancerPET Clinics, 2018
- Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancerBreast Cancer Research and Treatment, 2018
- [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast CancerMolecular Imaging and Biology, 2016
- Inverse Electron-Demand Diels–Alder Bioorthogonal ReactionsTopics in Current Chemistry, 2015
- A New Highly Reactive and Low Lipophilicity Fluorine-18 Labeled Tetrazine Derivative for Pretargeted PET ImagingACS Medicinal Chemistry Letters, 2015
- Pretargeted radioimmunotherapy: clinically more efficient than conventional radioimmunotherapy?European Journal of Nuclear Medicine and Molecular Imaging, 2013
- Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals and Positron Emission Tomography (PET)Accounts of Chemical Research, 2009